Healthcare provider profile · identity verified

Alberto Gutierrez, MD

Internal Medicine · GALVESTON, TX · NPI 1952742157

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	632	199
Losartan Potassium	Losartan Potassium	521	153
Amlodipine Besylate	Amlodipine Besylate	434	132
Rosuvastatin Calcium	Rosuvastatin Calcium	315	98
Omeprazole	Omeprazole	276	93
Gabapentin	Gabapentin	265	80
Levothyroxine Sodium	Levothyroxine Sodium	264	73
Furosemide	Furosemide	245	81
Pantoprazole Sodium	Pantoprazole Sodium	238	73
Metoprolol Succinate	Metoprolol Succinate	233	71
Tamsulosin Hcl	Tamsulosin Hcl	208	66
Metformin Hcl	Metformin Hcl	198	58
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	174	52
Eliquis	Apixaban	173	45
Lisinopril	Lisinopril	153	46
Tramadol Hcl	Tramadol Hcl	150	42
Trazodone Hcl	Trazodone Hcl	136	39
Hydrochlorothiazide	Hydrochlorothiazide	135	43
Metformin Hcl Er	Metformin Hcl	127	42
Carvedilol	Carvedilol	122	40
Meloxicam	Meloxicam	120	49
Ozempic	Semaglutide	114	34
Albuterol Sulfate Hfa	Albuterol Sulfate	111	25
Fluticasone Propionate	Fluticasone Propionate	109	49
Duloxetine Hcl	Duloxetine Hcl	99	32
Allopurinol	Allopurinol	93	31
Glipizide Er	Glipizide	93	29
Celecoxib	Celecoxib	92	22
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	88	33
Escitalopram Oxalate	Escitalopram Oxalate	88	31
Chlorthalidone	Chlorthalidone	82	26
Famotidine	Famotidine	77	25
Spironolactone	Spironolactone	75	25
Simvastatin	Simvastatin	72	20
Methylprednisolone	Methylprednisolone	70	64
Finasteride	Finasteride	69	22
Pravastatin Sodium	Pravastatin Sodium	66	20
Pioglitazone Hcl	Pioglitazone Hcl	64	25
Metoprolol Tartrate	Metoprolol Tartrate	62	23
Prednisone	Prednisone	61	49
Montelukast Sodium	Montelukast Sodium	60	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	59	17
Clopidogrel	Clopidogrel Bisulfate	58	25
Ezetimibe	Ezetimibe	57	20
Bupropion Xl	Bupropion Hcl	52	16
Mirtazapine	Mirtazapine	49	16
Enalapril Maleate	Enalapril Maleate	48	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	48	25
Alendronate Sodium	Alendronate Sodium	46	13
Buspirone Hcl	Buspirone Hcl	45	16
Pregabalin	Pregabalin	44	suppressed
Januvia	Sitagliptin Phosphate	43	13
Synthroid	Levothyroxine Sodium	43	12
Tizanidine Hcl	Tizanidine Hcl	42	11
Hydralazine Hcl	Hydralazine Hcl	40	15
Azelastine Hcl	Azelastine Hcl	38	15
Symbicort	Budesonide/Formoterol Fumarate	38	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Glipizide	Glipizide	36	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	36	19
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	35	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	35	14
Acetaminophen-Codeine	Acetaminophen With Codeine	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	13
Sertraline Hcl	Sertraline Hcl	34	11
Amitriptyline Hcl	Amitriptyline Hcl	32	11
Bumetanide	Bumetanide	32	12
Valacyclovir	Valacyclovir Hcl	32	16
Ofloxacin	Ofloxacin	31	28
Jardiance	Empagliflozin	30	13
Benazepril Hcl	Benazepril Hcl	29	11
Doxycycline Hyclate	Doxycycline Hyclate	29	24
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Valsartan	Valsartan	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	27	suppressed
Mounjaro	Tirzepatide	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	25	24
Entresto	Sacubitril/Valsartan	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	19
Clotrimazole	Clotrimazole	22	17
Propranolol Hcl	Propranolol Hcl	22	suppressed
Hydrocortisone	Hydrocortisone	21	18
Ondansetron Odt	Ondansetron	21	16
Atenolol	Atenolol	20	suppressed
Ketoconazole	Ketoconazole	20	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	19	18
Primidone	Primidone	19	11
Promethazine Hcl	Promethazine Hcl	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Clonazepam	Clonazepam	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Nebivolol Hcl	Nebivolol Hcl	17	suppressed
Azithromycin	Azithromycin	16	15
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Fluconazole	Fluconazole	16	16
Fluticasone-Salmeterol Hfa	Fluticasone Propion/Salmeterol	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Cephalexin	Cephalexin	14	13
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	13	13
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	12	suppressed
Nexium	Esomeprazole Magnesium	12	suppressed
Prozac	Fluoxetine Hcl	12	suppressed
Baclofen	Baclofen	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Digoxin	Digoxin	11	suppressed
Estradiol	Estradiol	11	suppressed
Phenytoin	Phenytoin	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error